ZA200604983B - Pharmaceutical composition which can be used in particular as an antiviral, antibacterial and for stimulating the immune defences - Google Patents
Pharmaceutical composition which can be used in particular as an antiviral, antibacterial and for stimulating the immune defences Download PDFInfo
- Publication number
- ZA200604983B ZA200604983B ZA200604983A ZA200604983A ZA200604983B ZA 200604983 B ZA200604983 B ZA 200604983B ZA 200604983 A ZA200604983 A ZA 200604983A ZA 200604983 A ZA200604983 A ZA 200604983A ZA 200604983 B ZA200604983 B ZA 200604983B
- Authority
- ZA
- South Africa
- Prior art keywords
- extract
- composition according
- extracts
- cyathea
- fagara
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 10
- 230000000844 anti-bacterial effect Effects 0.000 title claims abstract description 8
- 230000000840 anti-viral effect Effects 0.000 title claims abstract description 7
- 230000004936 stimulating effect Effects 0.000 title description 3
- 239000000284 extract Substances 0.000 claims abstract description 64
- 239000000203 mixture Substances 0.000 claims abstract description 37
- 241000196324 Embryophyta Species 0.000 claims description 34
- 241000723185 Cyathea Species 0.000 claims description 13
- 239000000463 material Substances 0.000 claims description 13
- 208000030507 AIDS Diseases 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 241000044532 Paspalum conjugatum Species 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 8
- 241000894007 species Species 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 5
- 229940121375 antifungal agent Drugs 0.000 claims description 4
- 235000008216 herbs Nutrition 0.000 claims description 4
- 241001330453 Paspalum Species 0.000 claims description 3
- 230000000843 anti-fungal effect Effects 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 2
- 241000209504 Poaceae Species 0.000 abstract 1
- 241001093501 Rutaceae Species 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 description 14
- 239000007788 liquid Substances 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 241000725303 Human immunodeficiency virus Species 0.000 description 7
- 210000000987 immune system Anatomy 0.000 description 7
- 229940088710 antibiotic agent Drugs 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 239000003242 anti bacterial agent Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 208000035143 Bacterial infection Diseases 0.000 description 3
- 239000001828 Gelatine Substances 0.000 description 3
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 208000022362 bacterial infectious disease Diseases 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 229940072221 immunoglobulins Drugs 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 208000031886 HIV Infections Diseases 0.000 description 2
- 208000037357 HIV infectious disease Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- YIWGJFPJRAEKMK-UHFFFAOYSA-N 1-(2H-benzotriazol-5-yl)-3-methyl-8-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carbonyl]-1,3,8-triazaspiro[4.5]decane-2,4-dione Chemical compound CN1C(=O)N(c2ccc3n[nH]nc3c2)C2(CCN(CC2)C(=O)c2cnc(NCc3cccc(OC(F)(F)F)c3)nc2)C1=O YIWGJFPJRAEKMK-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 241001410432 Cyathea manniana Species 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- PDLGMYVCPJOYAR-DKIMLUQUSA-N Glu-Leu-Phe-Ala Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](C)C(O)=O)CC1=CC=CC=C1 PDLGMYVCPJOYAR-DKIMLUQUSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 208000010040 Sprains and Strains Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 241001122767 Theaceae Species 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012675 alcoholic extract Substances 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- PZZYQPZGQPZBDN-UHFFFAOYSA-N aluminium silicate Chemical compound O=[Al]O[Si](=O)O[Al]=O PZZYQPZGQPZBDN-UHFFFAOYSA-N 0.000 description 1
- 229910000323 aluminium silicate Inorganic materials 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000003356 anti-rheumatic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000009519 contusion Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 239000000399 hydroalcoholic extract Substances 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007119 pathological manifestation Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 244000000000 soil microbiome Species 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Bioinformatics & Cheminformatics (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0310162A FR2859107B1 (fr) | 2003-08-26 | 2003-08-26 | Utilisation des extraits d'une graminee, d'une rutacee et d'une pieridophyte dans une composition pharmaceutique a activite antivirale, antibacterienne, antifongique et aussi destinee a stimuler les defenses immunitaires |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200604983B true ZA200604983B (en) | 2007-09-26 |
Family
ID=34130597
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200604983A ZA200604983B (en) | 2003-08-26 | 2006-06-19 | Pharmaceutical composition which can be used in particular as an antiviral, antibacterial and for stimulating the immune defences |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1675605B1 (de) |
AT (1) | ATE391511T1 (de) |
DE (1) | DE602004013034T2 (de) |
EA (1) | EA009393B1 (de) |
FR (1) | FR2859107B1 (de) |
WO (1) | WO2005021019A1 (de) |
ZA (1) | ZA200604983B (de) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR3021224B1 (fr) * | 2014-05-26 | 2017-11-17 | Henri Charles Ainadou | Phytomedicament pour le vih |
FR3021871B1 (fr) * | 2014-06-10 | 2018-07-13 | Aliou Mamadou Balde | Composition a base d'anthostema senegalense utilisee comme medicament contre le sida |
FR3113586A1 (fr) | 2020-08-29 | 2022-03-04 | Bruno Eto | Nouvelle utilisation thérapeutique de La Fagaricine comme médicament pour soigner les Hémoprotozooses sténoxènes des pays tropicaux |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK0384798T3 (da) * | 1989-02-06 | 1993-12-06 | Soma Genichiro | Limulustest-positivt planteglycolipid samt fremgangsmåde til stimulering af et dyrs immunsystem |
EP0503208A1 (de) * | 1991-03-08 | 1992-09-16 | Maracuyama International, S.A. | Verfahren zur Gewinnung eines natürlichen, wasserlöslichen Extraktes von Blättern und/oder Rhizomen aus verschiedenen Farnkräutern mit immunologischer Aktivität |
US5837257A (en) * | 1996-07-09 | 1998-11-17 | Sage R&D | Use of plant extracts for treatment of HIV, HCV and HBV infections |
JP3851829B2 (ja) * | 2002-02-28 | 2006-11-29 | 株式会社ノエビア | 皮膚表面散乱光増加を目的とした皮膚外用剤 |
-
2003
- 2003-08-26 FR FR0310162A patent/FR2859107B1/fr not_active Expired - Fee Related
-
2004
- 2004-08-26 DE DE602004013034T patent/DE602004013034T2/de active Active
- 2004-08-26 WO PCT/FR2004/002191 patent/WO2005021019A1/fr active IP Right Grant
- 2004-08-26 EP EP04786353A patent/EP1675605B1/de active Active
- 2004-08-26 EA EA200600466A patent/EA009393B1/ru not_active IP Right Cessation
- 2004-08-26 AT AT04786353T patent/ATE391511T1/de not_active IP Right Cessation
-
2006
- 2006-06-19 ZA ZA200604983A patent/ZA200604983B/en unknown
Also Published As
Publication number | Publication date |
---|---|
FR2859107B1 (fr) | 2008-04-18 |
DE602004013034D1 (de) | 2008-05-21 |
EA009393B1 (ru) | 2007-12-28 |
EP1675605A1 (de) | 2006-07-05 |
EA200600466A1 (ru) | 2006-08-25 |
EP1675605B1 (de) | 2008-04-09 |
FR2859107A1 (fr) | 2005-03-04 |
WO2005021019A1 (fr) | 2005-03-10 |
ATE391511T1 (de) | 2008-04-15 |
DE602004013034T2 (de) | 2009-05-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11166998B2 (en) | Eurycoma longifolia extract and its use in enhancing and/or stimulating immune system | |
KR100605292B1 (ko) | 신규한 오가피 및 오가피 열매, 가시오가피 다당체, 그제조방법 및 그를 활성성분으로 함유하는 항암제 조성물 | |
ZA200506723B (en) | Composition for treating hepatitis C | |
US20110250226A1 (en) | Composition containing extracts of fuscoporia obliqua, ganoderma lucidum and phellinus linteus for promoting the proliferation of hematopoietic stem cells | |
KR20160050108A (ko) | 천연물 추출물을 유효성분으로 포함하는 구강 위생 증진용 조성물 및 이의 용도 | |
CN101239091B (zh) | 防治幽门螺杆菌感染的组合物 | |
US20070248619A1 (en) | New pharmaceutical composition from natural materials for regulating immunity, its preparation method and use | |
Ita et al. | Haematopoietic properties of ethanolic leaf extract of ageratum conyzoides (goat weed) in albino rats. | |
CN101267859A (zh) | 用于治疗前列腺癌的含九里香碱的药物组合物 | |
ZA200604983B (en) | Pharmaceutical composition which can be used in particular as an antiviral, antibacterial and for stimulating the immune defences | |
WO1994018993A1 (en) | Therapeutic herbal composition | |
Barrett | Echinacea: A Safety Review. | |
AU760967B2 (en) | Herbal composition for the prophylaxis and treatment of AIDS | |
KR20050047579A (ko) | 혼합생약재를 이용한 골질환 예방 및 치료용 약제 조성물 | |
WO2004112692A2 (en) | Therapeutic herbal compositions | |
WO1995008318A2 (fr) | Substance medicinale a proprietes anti-infecteuses destinee a etre utilisee dans le traitement de la sterilite et dans la protection de la grossesse | |
US7160561B2 (en) | Herbal composition and method of treating HIV infection | |
US20040258712A1 (en) | Herbal composition containing sea salt | |
US20020006446A1 (en) | Botanical combinations for treating AIDS and immune-deficient patients to maintain good health and the process for preparing the same | |
Abue et al. | Using African alternative medicine to curb Covid-19: A case study of SAAAB, SAABFAT6, and SAABMAL HERBAL SUPPLEMENTS | |
JP2008247797A (ja) | 成人t細胞性白血病の予防剤、治療剤、及びその医薬品組成物 | |
CN100443093C (zh) | 治疗艾滋病的药物 | |
Nnumolu et al. | Effect of Citrullus lanatus Seeds Extract on Haematological Parameters After Administration with Medroxyprogesterone Acetate on Female Wistar Rats | |
Islam et al. | Assessment of Pharmacological Properties of Mimosa Diplotricha Leaf Extract | |
CN117323362A (zh) | 一种抗幽门螺杆菌的植物挥发油组合物 |